Risks

Negative interest coverage and modest net leverage versus profitable peers leave AQST more exposed to refinancing or dilution if commercialization ramps slower than expected.

A long cash conversion cycle driven by high inventory and receivables days can pressure working capital versus leaner specialty-pharma peers, constraining flexibility during launch execution.

Dependence on a small number of marketed products increases demand concentration risk versus broader neurology or rare-disease peers, making revenue more sensitive to payer or prescribing shifts.

High payables days partly offset liquidity needs, but the structure can tighten supplier terms over time versus peers with stronger operating cash generation and FCF visibility.

Opportunities

AQST’s very strong current and quick ratios provide materially better near-term liquidity than many development-stage peers, supporting launch investment and reducing balance-sheet stress.

Low net debt relative to EBITDA gives AQST more financial runway than leveraged specialty-pharma peers, improving its ability to absorb commercialization volatility and fund growth.

If product uptake continues, the company can convert its working-capital-heavy model into operating leverage faster than peers with weaker liquidity, amplifying margin expansion potential.

Compared with smaller commercial peers, AQST’s balance-sheet flexibility can support broader market access and promotional execution, which may improve demand capture in the next 1–5 years.

Overall Score

AQST’s strong liquidity and manageable leverage support commercialization upside versus peers, while concentration, working-capital intensity, and weak interest coverage keep downside risks meaningful but not dominant.